Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients
This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma.
Relapsed Large B-cell Lymphoma|Refractory Large B-cell Lymphoma|Diffuse Large B-cell Lymphoma (DLBCL)|Primary Mediastinal Large B-Cell Lymphoma (PMBCL)|High-grade B-cell Lymphoma|Transformed Follicular Lymphoma (TFL)
BIOLOGICAL: CRC01|DRUG: Fludarabine|DRUG: Cyclophosphamide
Phase 1 Study: Maximum Tolerated Dose (MTD) which will be the Recommended Phase 2 Dose (RP2D), 28 days|Phase 2 Pivotal Study: Overall Response Rate (ORR), ORR is defined as the incidence of either a complete response (CR) or a partial response (PR) per the Lugano Criteria for Response Assessment (2014)., 5 years
Time to response (TTR), 5 years|Duration of overall response (DOR), 5 years|Event free survival (EFS), 5 years|Progression free survival (PFS), 5 years|Overall survival (OS), 5 years|Incidence and severity of adverse events (AEs), 5 years|Incidence of immunogenicity to CRC01, 5 years|Number of participants with presence of exposure to replication-competent lentivirus (RCL) as Assessed by quantitative polymerase chain reaction (qPCR), 5 years|Incidence of secondary malignancy, 5 years|Peak concentration (Cmax) of CRC01 transduced cells into target tissues, 5 years|Area under the concentration versus time curve (AUC) of CRC01 transduced cells into target tissues, 5 years|Time to maximum observed concentration (Tmax) of CRC01 transduced cells into target tissues, 5 years
This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma.